⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5711100 | 1.00 | — | — | |
| SCHEMBL2366043 | 1.00 | — | — | |
| SCHEMBL9550079 | 0.83 | LMNA (0.65) | — | |
| SCHEMBL2518366 | 0.81 | MAOA (0.40) | — | |
| SCHEMBL2518363 | 0.81 | MAOA (0.40) | — | |
| SCHEMBL19341993 | 0.81 | LMNA (0.58) | — | |
| SCHEMBL19341994 | 0.81 | LMNA (0.58) | — | |
| SCHEMBL19341995 | 0.81 | LMNA (0.58) | — | |
| SCHEMBL13981360 | 0.79 | LMNA (0.53) | — | |
| SCHEMBL9213532 | 0.79 | LMNA (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023230609-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| EP-3567030-B1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-11040984-B2 | Quinazoline compound for EGFR inhibition | MEDSHINE DISCOVERY INC. (CN) | 2021-06-22 | — | — | US | disclosed |
| US-11040984-B2 | Quinazoline compound for EGFR inhibition | MEDSHINE DISCOVERY INC. (CN) | 2021-06-22 | — | — | US | disclosed |
| US-20200190107-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200190107-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3567030-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
| EP-3567030-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018121758-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | 南京明德新药研发股份有限公司 | 2018-07-05 | — | — | WO | disclosed |
| US-9839641-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| WO-2017156181-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2017-05-11 | — | — | US | disclosed |
| US-9540394-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| US-20160130281-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2016-05-12 | — | — | US | disclosed |
| EP-2948461-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | Entasis Therapeutics Limited (GB) | 2015-12-02 | — | — | EP | disclosed |
| US-9187495-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20150203513-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2015-07-23 | — | — | US | disclosed |
| US-8889671-B2 | Compounds and methods for treating bacterial infections | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| WO-2014114929-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2014-07-31 | — | — | WO | disclosed |
| US-20140206677-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |